期刊
BLOOD
卷 120, 期 2, 页码 291-294出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-01-407486
关键词
-
类别
资金
- National Institute for Health Research Biomedical Research Center Funding Scheme, United Kingdom
- Novartis
- Bristol Myers-Squibb
- Cancer Research UK [10411] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0611-10275] Funding Source: researchfish
Dasatinib is effective therapy for newly diagnosed patients with chronic myeloid leukemia, but not all patients respond well. We analyzed the outcome of patients treated with dasatinib as first-line therapy to identify patients who are more likely to fare poorly. The 8.6% of patients who at 3 months had a BCR-ABL1/ABL1 ratio > 10% had a significantly worse 2-year cumulative incidence of complete cytogenetic response (58.8% vs 96.6%, P < .001) and molecular responses than the remaining patients with a lower transcript levels. The predictive value of the 3-month transcript level could be improved using the dasatinib-specific transcript level cut-offs, namely, 2.2%, 0.92%, and 0.57% for complete cytogenetic response, 3 log and 4.5 log reductions in the transcript level, respectively. The study was registered at www.clinicaltrials.gov as #NCT01460693. (Blood. 2012;120(2):291-294)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据